Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TAK-733||TAK733||MEK inhibitor (Pan) 23 MEK1 Inhibitor 22 MEK2 Inhibitor 20||TAK-733 inhibits MEK1 and MEK2, preventing the activation of the RAS/RAF/MEK/ERK pathway, possibly inhibiting growth factor-mediated cell signaling and tumor cell proliferation (PMID: 26439693, PMID: 30396931).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF mut PIK3CA wild-type||colorectal cancer||predicted - sensitive||TAK-733||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).||26439693|
|NRAS mut PIK3CA wild-type||colorectal cancer||predicted - sensitive||TAK-733||Preclinical - Cell culture||Actionable||In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).||26439693|
|BRAF L597S||melanoma||sensitive||TAK-733||Phase I||Actionable||In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-733 (PMID: 22798288).||22798288|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|